ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1730

Osteoarthritis Is a Risk Factor for Inflammatory Arthritis in Cancer Patients Treated with Immune Checkpoint Inhibitors

Daniel Portnoy1, Matthieu J Piola2, Luke Hao2, Robert Winchester2, Adam Mor2 and Yevgeniya Gartshteyn3, 1Columbia University Irving Medical Center, New Yok, NY, 2Columbia University Irving Medical Center, New York, NY, 3Columbia University Irving School of Medicine, New York, NY

Meeting: ACR Convergence 2024

Keywords: immunology, Inflammation, Osteoarthritis

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 17, 2024

Title: Abstracts: Immunological Complications of Medical Therapy

Session Type: Abstract Session

Session Time: 3:00PM-4:30PM

Background/Purpose: Inflammatory arthritis is one of the most common immune-related adverse events (irAEs) resulting from immune checkpoint inhibitors (ICIs). We hypothesized that T cells present in joints damaged by osteoarthritis (OA) are primed for ICI induced on-target off-tumor immune responses, resulting in increased irAE-arthritis risk in OA.

Methods: This case-control study evaluated the prevalence of OA in ICI treated patients who develop inflammatory irAE-arthritis (cases) vs. other irAEs (non-arthritis) vs. no irAEs (controls). We defined OA based on the ICD-10 codes and/or Kellgren and Lawrence radiographic criteria. Synovial and peripheral blood mononuclear cells were analyzed using a multiparameter spectral flow panel, followed by unsupervised clustering, UMAP dimensionality reduction and enrichment analysis.

Results: 108 patients who received ICI treatment were included in the study: 31 with irAE-arthritis, 38 with non-arthritis irAE, and 39 with no irAEs. Patient characteristics are summarized in Table 1.  The prevalence of OA was increased in the irAE-arthritis group (83.9%) as compared to 28.9% (p< 0.001) in non-arthritis irAEs and 35.9% (p< 0.001) in the no irAEs groups, Fig.1A. In multivariable analyses, irAE-arthritis was independently associated with the presence of OA (OR 75.5, 95% CI 6.3-685.5), history of smoking (OR 16.5, 95% CI2.0-137.6) and BMI (OR 1.2, 95% CI 1.1-1.4) when controlling for age, gender and race. The prevalence of OA in the irAE-arthritis-affected joints is shown in Fig 1B.

Analysis of OA synovial fluid (ICI untreated) identified the presence of CD8+ and CD4+ αβ T lymphocytes (58.55±61.50 cells/uL) which highly express PD-1. Of these, 30% had the phenotype of resident memory T cells (CD69+ CD103+). Following ICI treatment, analysis of PBMCs from OA patients revealed an expanded CD4+ T cell cluster 6 in irAE-arthritis as compared to non-arthritis irAE (p< 0.05) or no irAEs (p=0.05), Fig 2. Further analysis identified this cluster as an unusual memory CD4+ T cell subset expressing CCR4 and CXCR3, but lacking CCR6 and CD161. Additionally, we found expanded CD8+ TEMRA cells in irAE-arthritis vs. non-arthritis irAE (p=0.02).

Conclusion: There is a significant association between irAE-arthritis and the prevalence of OA in the affected joints. Resident memory T cells present in the OA synovial fluid may contribute to the development of irAE-arthritis. Expanded CD8+ TEMRA and CD4+ memory CCR4+CXCR3+ T cell populations were found in OA patients who develop irAE arthritis compared to controls.  

* These authors contributed equally to this work.

Supporting image 1

Table 1. Patient Characteristics.

Supporting image 2

Figure 1. A. The prevalence of osteoarthritis, stratified by age, in ICI-treated patients with irAE-arthritis, non-arthritis irAE and no irAEs. B. The prevalence of radiographic osteoarthritis in irAE-arthritis-affected joints.

Supporting image 3

Figure 2. Peripheral blood mononuclear cells (PBMCs) isolated from ICI-treated patients with baseline osteoarthritis were analyzed using multiparameter flow cytometry. Uniform Manifold Approximation and Projection (UMAP) dimensionality reduction was performed for T cell cluster visualization followed by cluster annotation (top left); expression of select cell surface markers is shown in the bottom panels. Expansion of cluster 6 in irAE-arthritis as compared to non-arthritis irAE or no irAEs is shown (box plot), with specific cell surface markers of cluster 6 shown on the right.


Disclosures: D. Portnoy: None; M. Piola: None; L. Hao: None; R. Winchester: None; A. Mor: None; Y. Gartshteyn: None.

To cite this abstract in AMA style:

Portnoy D, Piola M, Hao L, Winchester R, Mor A, Gartshteyn Y. Osteoarthritis Is a Risk Factor for Inflammatory Arthritis in Cancer Patients Treated with Immune Checkpoint Inhibitors [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/osteoarthritis-is-a-risk-factor-for-inflammatory-arthritis-in-cancer-patients-treated-with-immune-checkpoint-inhibitors/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/osteoarthritis-is-a-risk-factor-for-inflammatory-arthritis-in-cancer-patients-treated-with-immune-checkpoint-inhibitors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology